Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Mushroom-Based pill cut surgery complications in colon cancer?

NCT ID NCT04821258

Prevention Sponsor: Fundacin Biomedica Galicia Sur Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a supplement made from nine fungal extracts, called MICODIGEST 2.0, can reduce complications after surgery for colorectal cancer. The trial enrolls 48 adults scheduled for curative-intent surgery. Half receive the supplement and half receive a placebo, and researchers compare rates of infections, anastomotic failure, and other problems, along with changes in gut bacteria and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a nutraceutical supplement made from nine fungal extracts, including reishi, shiitake, and cordyceps
What this could lead to
If it works, this could offer a low-cost, easy-to-take supplement that helps people recover from colorectal cancer surgery with fewer infections and other complications.
What could go wrong
This is a small, early-stage trial of 48 people, so any hint of benefit could be chance. Supplements can interact with other treatments, and the fungal extracts may not change surgical outcomes at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Jun 2021

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. CRC patients who are candidates for surgical treatment with curative intent (risk I-III). 2. American Society of Anesthesiologists' Physical Status Classification (ASA) \<3. 3. Patients aged between 18 and 85 years. 4. Eastern Cooperative Oncology Group (ECOG) scale between 0-2. 5. Patients with preserved cognitive function. 6. Patient's authorization after reading the study information sheet. Exclusion Criteria: 1. Candidates for neoadjuvant therapy. 2. Patients with concomitant carcinoma. 3. Allergy to the supplied nutraceutical or presence of malabsorption syndrome. 4. Presence of mental disorders 5. Patient with active infection or antibiotic therapy in the last month. 6. Previous colorectal surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Surgery--complications

Contacts and locations

Locations

  • Complexo Hospitalario Universitario de Ourense

    Ourense, 32002, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.